X
BIO icon

Xponance’s Bio-Rad Laboratories Class A BIO Stock Holding History

Xponance’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639K Sell
2,176
-49
-2% -$13.9K ﹤0.01% 986
2026
Q1 		$620K Buy
2,225
+527
+31% +$152K ﹤0.01% 922
2025
Q4 		$514K Sell
1,698
-367
-18% -$115K ﹤0.01% 939
2025
Q3 		$579K Sell
2,065
-68
-3% -$18.5K ﹤0.01% 915
2025
Q2 		$515K Sell
2,133
-1,075
-34% -$254K ﹤0.01% 940
2025
Q1 		$781K Sell
3,208
-17
-0.5% -$5.11K 0.01% 785
2024
Q4 		$1.06M Buy
3,225
+97
+3% +$32.9K 0.01% 703
2024
Q3 		$1.05M Buy
3,128
+330
+12% +$105K 0.01% 686
2024
Q2 		$764K Sell
2,798
-263
-9% -$76.5K 0.01% 769
2024
Q1 		$1.06M Buy
3,061
+327
+12% +$108K 0.01% 701
2023
Q4 		$883K Sell
2,734
-562
-17% -$176K 0.01% 719
2023
Q3 		$1.18M Buy
3,296
+135
+4% +$52.1K 0.02% 602
2023
Q2 		$1.2M Buy
3,161
+211
+7% +$85.9K 0.02% 607
2023
Q1 		$1.41M Sell
2,950
-9
-0.3% -$4.21K 0.02% 546
2022
Q4 		$1.24M Buy
2,959
+562
+23% +$227K 0.02% 569
2022
Q3 		$1M Buy
2,397
+312
+15% +$156K 0.02% 578
2022
Q2 		$1.03M Sell
2,085
-4,387
-68% -$2.28M 0.02% 562
2022
Q1 		$3.65M Sell
6,472
-6,376
-50% -$3.84M 0.06% 251
2021
Q4 		$9.71M Buy
12,848
+260
+2% +$195K 0.15% 115
2021
Q3 		$9.39M Buy
12,588
+7,102
+129% +$5.32M 0.18% 98
2021
Q2 		$3.54M Sell
5,486
-1,228
-18% -$747K 0.07% 243
2021
Q1 		$3.83M Buy
6,714
+1,352
+25% +$801K 0.08% 201
2020
Q4 		$3.13M Buy
5,362
+4,504
+525% +$2.57M 0.07% 235
2020
Q3 		$442K Sell
858
-34
-4% -$17.2K 0.01% 704
2020
Q2 		$403K Buy
+892
New +$394K 0.01% 702

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Xponance's BIO Position: Q2 2026 in Review

Xponance reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.2% in Q2 2026, selling an estimated $13.9K and leaving 2,176 shares worth $639K. The position accounts for ﹤0.01% of the portfolio, ranked #986.

Xponance first reported a position in BIO in Q2 2020 and has held it in 25 quarters since. The position peaked at $9.71M in Q4 2021. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Xponance held 2,176 shares of Bio-Rad Laboratories Class A worth $639K as of Q2 2026.
  • Xponance sold 49 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $13.9K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #986 holding.
  • Xponance first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Bio-Rad Laboratories Class A position peaked at $9.71M in Q4 2021.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.